Cardiolipin

Cardiolipin: A Comprehensive Reference

1. Identity: Chemical Name, Structure, and Natural Sources

1.1 Nomenclature and Chemical Identity

Cardiolipin has a diphosphatidylglycerol (DPG) structure, and its full systematic chemical name is 1,3-bis(sn-3′-phosphatidyl)-sn-glycerol. It is also designated in lipid shorthand as diphosphatidylglycerol (DPG). Cardiolipin, the signature phospholipid of mitochondria, is a lipid dimer. The structure consists of two phosphatidyl groups bridged by a glycerol. The four acyl chains distinguish it from typical phospholipids, which have only two acyl chains.

Cardiolipin possesses a distinctive structure consisting of dimeric phospholipids linked by a glycerol moiety at the head group. Even with four identical acyl residues, cardiolipin has two chemically distinct phosphatidyl moieties located at two chiral centres, one in each outer glycerol group; natural cardiolipin has the R/R configuration. Cardiolipin thus carries a double negative charge at physiological pH.

The predominant acyl chain constituent of mammalian cardiolipin in cells of natural organisms is linoleic acid (18:2ω6). The fatty acid composition of naturally occurring cardiolipin is generally distributed among palmitoyl (16:0), stearoyl (18:0), oleoyl (18:1), and linoleoyl (18:2). The most abundant fatty acid molecular species in naturally occurring forms of cardiolipin are linoleic acid at approximately 90%, followed by oleic acid at 5%, and palmitic acid at 1%.

1.2 Natural Sources

Cardiolipin is a unique phospholipid of the inner mitochondrial membrane (IMM) as well as in bacteria. Cardiolipin is a constituent of the mitochondrial membrane and can be extracted from a number of natural sources such as ox liver, ox heart, rat liver, and several plants.

It can be derived, for example, by solvent extraction of beef heart muscle tissue, by a precipitation method, or by high pressure column chromatography. In prokaryotes such as bacteria, cardiolipin (diphosphatidylglycerol) synthase (CLS) catalyses a transfer of the phosphatidyl moiety of one phosphatidylglycerol to the free 3′-hydroxyl group of another, with the elimination of one molecule of glycerol.

Because cardiolipin is found in essentially all eukaryotic cells and in many bacteria—any tissue rich in mitochondria (heart muscle, liver, skeletal muscle, brain) is correspondingly rich in cardiolipin. Mitochondria provide 95% of the energy demand in the heart, particularly due to their role in fatty acid oxidation, and heart muscle is therefore among the richest dietary and commercial sources of cardiolipin.

1.3 Common Forms and Preparations

Cardiolipin is commercially available in several forms for research and experimental purposes. Forms documented in the scientific literature include: native bovine-heart cardiolipin (the most common natural extract used in research), tetraoleoyl-cardiolipin (TOCL, composed of four oleic acid constituents, C18:1), tetralinoleoyl-cardiolipin (TLCL, composed primarily of linoleic acid acyl chains), and their lyso-derivatives (monolysocardiolipin and dilysocardiolipin). Tetraoleoyl-cardiolipin is composed of four oleic acid constituents (C18:1), which are less susceptible to oxidative damage and breakdown than linoleic acid cardiolipins.

As a dietary supplement, cardiolipin is not widely marketed as an isolated ingredient in human formulations; rather, it is encountered primarily as a research-grade lipid or as a naturally occurring constituent of organ-meat-based foods. A distinct pharmacological approach involves cardiolipin-targeting peptides such as elamipretide (SS-31), which interact with endogenous cardiolipin and have been investigated in formal clinical trials (see Section 5 below).

2. Discovery and Historical Context

2.1 Initial Discovery

In 1941, Mary C. Pangborn, from the Division of Laboratories and Research, New York State Department of Health in Albany, New York, purified the syphilis antigen responsible for a positive Wassermann test. Because the antigen is a phospholipid extracted from beef hearts, she named it cardiolipin.

The earliest description of antibodies against phospholipids dates back to the development of a complement binding assay to diagnose syphilis by August von Wassermann in 1906, and the discovery by Mary Pangborn that the relevant antigen in this assay was a phospholipid, later called cardiolipin.

It was not until 1941 that cardiolipin (CL, diphosphatidylglycerol), isolated and prepared by Pangborn, was identified as the antigen to which the Wassermann antibodies bound. In 1965, de Haas and Van Deenen were able to synthesize the compound, and they showed that binding of syphilis sera to this synthetic product was little different from binding of cardiolipin obtained from natural sources.

2.2 Role in Syphilis Serology and the VDRL Test

Later, a flocculation test using suspension of liposomes containing cardiolipin, lecithin, and cholesterol was adopted as a serodiagnostic test for syphilis, referred to as the VDRL (Venereal Disease Research Laboratory) test.

Cardiolipin's role in syphilis diagnosis was foundational to twentieth-century serology, and its unexpected appearance in autoimmune contexts led to an entirely new field. However, as serological screening for syphilis became more widespread, it became evident that these tests were positive in many individuals with no symptoms of the disease. In the early 1950s, reports had appeared that biologically false positive syphilis tests were observed in patients with autoimmune disease.

2.3 Antiphospholipid Syndrome and Anticardiolipin Antibodies

In 1983, a specific radioimmunoassay was developed which detected antibodies against cardiolipin (aCL). Since aCL were found to be associated with thrombosis and pregnancy morbidity, the term anticardiolipin syndrome was introduced. Studies in Hughes' laboratory showed the link between anticardiolipin antibodies and stroke, deep vein thrombosis (DVT), recurrent pregnancy loss, livedo, seizures, and other conditions.

Antiphospholipid syndrome (APS) is defined as an autoimmune disease characterised by the presence of antiphospholipid antibodies and at least one thrombotic clinical manifestation or history of recurrent foetal loss. Although the association between the phenomenon of lupus anticoagulant, the presence of cardiolipin antibodies, and the development of various thrombotic events dates back to the mid-twentieth century, it was not until 1983 that these findings were grouped as a separate clinical entity.

This immunological history is important for understanding cardiolipin as a biomarker and a target of autoimmune pathology, quite distinct from its direct biochemical roles in cell biology. The term "cardiolipin" as a supplement or natural health ingredient entered scientific conversation much later, driven by twentieth- and twenty-first-century mitochondrial biology research.

3. Biosynthesis and Key Biochemical Properties

3.1 Biosynthesis in Eukaryotes

Unlike the other phospholipids, CL is synthesized almost exclusively within the mitochondrion to yield a nascent form of this phospholipid with non-uniform acyl chains composition. The synthesis of CL initiates from phosphatidylglycerol (PG) that is transported from the endoplasmic reticulum (ER) to the inner mitochondrial membrane.

The process of cardiolipin biosynthesis results in the production of immature cardiolipin. A subsequent step is required for its maturation when its acyl groups are replaced with unsaturated acyl chains, primarily linoleic acid. Linoleic acid is the major fatty acid of cardiolipin across all organs and tissues, except for the brain. Linoleic acid is not synthesized by mammalian cells. This means that the acyl chain composition of mature cardiolipin is critically dependent on dietary linoleic acid availability.

The remodeling of nascent cardiolipin into its mature, linoleic acid-enriched form is catalyzed by the enzyme tafazzin (encoded by the TAZ gene). Tafazzin catalyzes the final step in the remodeling of cardiolipin (CL), a glycerophospholipid located in the inner mitochondrial membrane. This unique feature is not derived from the de novo biosynthesis of CL, but rather from a remodeling process that involves phospholipases and transacylase/acyltransferase.

3.2 Physicochemical Properties

The four acyl chains present in cardiolipin offer a unique advantage over other phospholipids with only two acyl chains, as they can form significantly stronger and intricate covalently bonded structures via oxidative polymerization.

At neutral pH, cardiolipin exhibits a single positive charge, as a single proton becomes sequestered within a bicyclic resonance structure generated by the two phosphates and the central hydroxyl group. The unique feature of cardiolipin structure—the presence of two phosphate groups—can provide two negative charges, a fact that may become important for protein cross-links and protein-protein interactions.

CL is highly sensitive to oxidative damages by reactive oxygen species (ROS) due to its high content in polyunsaturated fatty acids and its location near the site of ROS production.

4. Mechanisms of Action and Core Biological Functions

4.1 Structural Role in the Inner Mitochondrial Membrane

CL is a unique phospholipid which is localized and synthesized in the inner mitochondrial membrane (IMM). It is now widely accepted that CL plays a central role in many reactions and processes involved in mitochondrial function and dynamics. Cardiolipin interacts with and is required for optimal activity of several IMM proteins, including the enzyme complexes of the electron transport chain (ETC) and ATP production and for their organization into supercomplexes. Moreover, CL plays an important role in mitochondrial membrane morphology, stability and dynamics, in mitochondrial biogenesis and protein import, in mitophagy, and in different mitochondrial steps of the apoptotic process.

Cardiolipin performs several vital functions such as resisting osmotic rupture and stabilizing the supramolecular structure of large membrane proteins, like ATP synthases and respirasomes.

4.2 Role in Oxidative Phosphorylation and ATP Synthesis

Cardiolipin (CL) is a phospholipid exclusively localized in the inner mitochondrial membrane where it is required for oxidative phosphorylation, ATP synthesis, and mitochondrial bioenergetics. The biological functions of CL are thought to depend on its acyl chain composition, which is dominated by linoleic acids in metabolically active tissues.

CL interacts with and is required for full activity of respiratory chain complexes, as well as for their assembly and stability. An absolute requirement for CL in the function of crucial mitochondrial proteins, e.g., cytochrome oxidase and the adenine nucleotide translocase, are likely additional factors impacting apoptosis and cellular energy homeostasis.

Specifically, one cardiolipin molecule is bound close to the site of ubiquinone reduction and is believed to ensure the stability of the catalytic site as well as being involved in proton uptake.

4.3 Role in Apoptosis (Programmed Cell Death)

CL influences the activity of electron transport chain enzyme complexes as well as members of the Bcl-2 family. Interactions between Bcl-2 family members and other pro-apoptotic enzymes have been shown to be crucial for the transduction of the apoptotic signalling cascades during programmed cell death.

Targeting of tBid to the mitochondria, which is necessary for Bax/Bak oligomerization and cristae remodelling, is dependent on the exposure of CL at contact sites between the inner and outer mitochondrial membranes. Also, the mobilization of cytochrome c, another key apoptotic event, is tightly regulated by the oxidative state of cardiolipin.

The lipid (CL)-bound form of cytochrome c is thought to initiate apoptosis via a lipid transfer step involving mitochondrially targeted Bid. A direct relationship between CL loss and cytochrome c release from the mitochondria has been identified as an initial step in the pathway to apoptosis.

Upon mitochondrial stress, CL is externalized on the outer mitochondrial membrane forming a binding platform for the specific recruitment of signaling molecules. CL microdomains play a role in autophagy, apoptosis, and inflammasome signaling.

4.4 Susceptibility to Oxidative Damage

Cardiolipin is particularly susceptible to ROS attack due to its high content of unsaturated fatty acids. Oxidative damage to cardiolipin would negatively impact the biochemical function of the mitochondrial membranes, altering membrane fluidity, ion permeability, structure and function of components of the mitochondrial electron transport chain, resulting in reduced mitochondrial oxidative phosphorylation efficiency and apoptosis.

CL is the only phospholipid in mitochondria that undergoes early oxidation during apoptosis. Pathological CL remodeling has been implicated in the etiology of mitochondrial dysfunction associated with a host of pathophysiological conditions including diabetes, obesity, heart failure, hyperthyroidism, neurodegeneration, and aging, all of which are characterized by increased levels of oxidative stress, CL deficiency, and enrichment of docosahexaenoic acid (DHA) content in CL.

Accumulation of oxidized CL and their depletion are mitochondrial hallmarks of aging.

5. Scientific Evidence by Area of Use

5.1 Barth Syndrome (Genetic Cardiolipin Deficiency)

Disease background: The most widely characterized clinical phenotypes of Barth syndrome (BTHS) are cardiomyopathy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria. The gene locus was mapped to Xq28, with mutations identified in G4.5, now referred to as the tafazzin (TAZ) gene. Tafazzin is a mitochondrial acyltransferase involved in remodeling cardiolipin (CL), the signature phospholipid of the inner mitochondrial membrane. Mutations in the TAZ gene resulting in either the complete loss of tafazzin or the expression of truncated tafazzin lead to BTHS.

A recent review has estimated the prevalence of BTHS as 1 case per million males. BTHS patients experience a high infant mortality rate due to progressive cardiomyopathy and a compromised immune system.

Mechanism linking tafazzin deficiency to disease: TAFAZZIN encodes for an enzyme involved in the final remodeling step of cardiolipin, a key phospholipid localized to the mitochondrial inner membrane. TAFAZZIN deficiency results in abnormal mitochondrial cardiolipin quantity and composition and subsequent mitochondrial dysfunction.

Clinical evidence — elamipretide (a cardiolipin-targeting peptide) in Barth syndrome: In addition to demonstrating the effects of cardiolipin targeting in cellular models of TAFAZZIN deficiency, this approach has shown clinical promise. In a recent study published in Genetics in Medicine, clinical researchers at the Johns Hopkins School of Medicine described results of a placebo-controlled, crossover clinical trial to investigate the role of elamipretide in 12 patients affected by Barth syndrome. The study participants showed improvement in multiple clinical parameters, including muscle strength, exercise tolerance, and cardiac stroke volume, after 48 weeks of treatment.

Evidence strength: The association between cardiolipin deficiency and Barth syndrome is firmly established at the molecular and genetic level. Human clinical trial evidence for cardiolipin-targeting therapy (elamipretide) in BTHS is preliminary but promising, based on a small crossover trial (n=12). Larger confirmatory trials are required.

5.2 Heart Failure and Cardiac Disease

Preclinical evidence — dietary linoleic acid and cardiolipin preservation: Cardiolipin (CL) is a tetra-acyl phospholipid that provides structural and functional support to several proteins in the inner mitochondrial membrane. The majority of CL in the healthy mammalian heart contains four linoleic acid acyl chains (L4CL). A selective loss of L4CL is associated with mitochondrial dysfunction and heart failure in humans and animal models.

Male spontaneously hypertensive heart failure rats (21 months of age) were administered diets supplemented with high-linoleate safflower oil (HLSO) or lard (10% w/w; 28% kilocalorie fat) or without supplemental fat (control) for 4 weeks. HLSO preserved L4CL and total CL to 90% of non-failing levels. The study demonstrates that supplementing the diet with HLSO, limiting total fat consumption to less than 30% of kilocalorie intake, increases L4CL and total CL content in LV mitochondria and attenuates the cardiac mitochondrial respiratory dysfunction associated with advanced hypertensive heart disease. HLSO also attenuated LV contractile dysfunction compared with the lard and control diets, but had no effect on blood pressure.

Dysfunctional CL has been found in diabetic cardiomyopathy, ischemia reperfusion injury, and the aging heart. Defects in the biosynthesis and remodeling of CL have a strong impact on mitochondrial function and particularly affect tissues with a high energetic contribution of mitochondria, such as the heart and neuronal tissue.

Elamipretide in broader heart failure populations: Preclinical studies showed benefit in cognitive impairment, muscle aging, atherosclerosis, osteoarthritis, diabetes, glaucoma, and other conditions, but clinical trials in heart failure and primary mitochondrial myopathy have failed to meet primary endpoints. Doses of 4 and 40 mg once daily (subcutaneous) were tested in a phase 2 double-blind randomized controlled trial in heart failure.

Evidence strength: Animal and mechanistic evidence linking CL integrity to cardiac function is robust. However, clinical evidence for dietary or supplemental interventions in humans is very limited. Elamipretide phase 2/3 trials in broader heart failure populations have not met their primary endpoints; the evidence for cardiolipin-targeting strategies in general heart failure populations remains insufficient at this time.

5.3 Diabetes and Metabolic Disease

Using a shotgun lipidomics approach, researchers demonstrated the dramatic loss of abundant CL molecular species in STZ-treated hearts at the very earliest stages of diabetes, accompanied by a profound remodeling of the remaining CL molecular species. These alterations in CL metabolism occur within days after the induction of the diabetic state and precede triacylglycerol accumulation.

Through use of a shotgun lipidomics approach, CL molecular species content depletion and substantial CL molecular species remodeling were shown to precede the lipotoxic hallmarks of diabetic cardiomyopathy. These results demonstrate alterations in CL hydrolysis and remodeling at the earliest stages of diabetes and are consistent with a role for alterations in CL content in precipitating mitochondrial dysfunction in diabetic cardiomyopathy.

During aging and diabetes, the fatty acid composition of CL may undergo remodeling when C18:2 fatty acids can be replaced by arachidonic acid (C20:4, ω-6) or docosahexaenoic acid (C22:6, ω3).

Evidence strength: Preclinical (animal models and in vitro) evidence. No adequately powered human clinical trials have directly tested cardiolipin supplementation for the treatment or prevention of diabetes or diabetic cardiomyopathy. This remains an area of scientific interest with insufficient clinical evidence.

5.4 Aging and Age-Related Mitochondrial Decline

Physiological factors that modify CL acylation include ageing, dietary influences, and ischemia/reperfusion where the terminal events may be either necrosis or apoptosis.

The heart is rich in cardiolipin, a phospholipid acylated in four sites, predominately with linoleic acid. Whether or not aging alters the composition of cardiolipin acyl chains has been controversial. Measurement of the fatty acid concentration of cardiolipin in hearts of 4, 12, and 24 month old rats found that the concentration of linoleic acid was decreased in 24-month-old rats compared to 4-month-old rats, while the concentrations of arachidonic and docosahexaenoic acid were increased. Similar changes were not observed in ethanolamine glycerophospholipids or plasma unesterified fatty acids, suggesting specificity of these effects to cardiolipin.

Disorders of CL remodeling have been reported in many clinical conditions including low fat diet, aging, obesity, diabetes, heart failure, and in Barth syndrome.

Evidence strength: Predominantly animal and biochemical evidence. The age-related decline in cardiolipin linoleic acid content is documented in rodent models but human longitudinal data directly quantifying cardiolipin changes with aging are limited. No human clinical trials have tested exogenous cardiolipin supplementation specifically for anti-aging outcomes.

5.5 Neurological and Neurodegenerative Diseases

CL plays a key role in mitochondrial membranes, impacting a plethora of functions this organelle performs. Consequently, abnormalities in the CL content, composition, and level of oxidation may negatively impact mitochondrial function and dynamics, with important implications in a variety of diseases.

Parkinson's disease (PD) is defined by the progressive loss of dopaminergic neurons and the accumulation of misfolded α-synuclein (α-syn), yet the molecular determinants of selective neuronal vulnerability remain unresolved. Increasing evidence implicates mitochondria—and particularly their membranes—as critical platforms where α-syn is toxic. A pivotal mediator of these events is cardiolipin (CL), a mitochondria-specific phospholipid essential for cristae organization and quality control pathways. Despite extensive progress, the precise mechanistic contributions of CL to α-syn aggregation, phase transitions, and neuronal degeneration remain poorly defined.

In the early pathology of Type II diabetes, oxidized CL has been observed in circulating plasma. Altered CL profiles have been observed in Alzheimer's and Parkinson's Disease. Neuronal specific CL has been found in circulating blood and used to predict injury severity in rodent models of pediatric traumatic brain injury and adult cardiac arrest.

Evidence strength: Biochemical and cell/animal model evidence only. No controlled human clinical trials have evaluated cardiolipin supplementation or cardiolipin-targeted therapy specifically for Alzheimer's disease, Parkinson's disease, or other neurodegenerative conditions in humans. Elamipretide's neuroprotective effects, observed in models of cognitive impairment by promoting mitochondrial and synaptic health and decreasing inflammation and pyroptosis, have not been confirmed in humans.

5.6 Ischemia-Reperfusion Injury

Following ischemia/reperfusion injury, mitochondrial dynamics are impacted, resulting in a dysfunctional mitochondrial network, inadequate energy reserves, and impaired cell health. CL is an essential phospholipid found on the IMM that contributes to cristae structure, membrane curvature, and cellular respiration.

Alterations in cardiolipin structure, content, and acyl chains composition have been associated with mitochondrial dysfunction in multiple tissues in several physiopathological conditions, including ischemia/reperfusion, different thyroid states, diabetes, aging, and heart failure.

Elamipretide was tested in acute myocardial infarction with percutaneous coronary intervention in a phase 2a clinical trial. A dose of 0.05 mg/kg/hr for 1 hour was used in that phase 2a clinical trial in patients with acute myocardial infarction with percutaneous coronary intervention. Results from these trials did not demonstrate statistically significant benefit on primary endpoints, though this remains an active investigational area.

Evidence strength: Mechanistic evidence linking CL oxidation to ischemia-reperfusion injury is well-established in animal models. Human clinical evidence for cardiolipin-targeted therapeutic strategies in this context is preliminary and has not met primary endpoints in trials conducted to date.

6. Body Systems and Health Areas Associated with Cardiolipin

• Cardiovascular System: CL is indispensable for cardiac mitochondrial bioenergetics. The majority of CL in the healthy mammalian heart contains four linoleic acid acyl chains (L4CL). A selective loss of L4CL is associated with mitochondrial dysfunction and heart failure in humans and animal models.
• Skeletal Muscle: Deficient CL remodeling causes Barth syndrome, a rare X-linked genetic disorder associated with a broad range of clinical manifestations, including cardiomyopathy, skeletal myopathy, neutropenia, and 3-methylglutaconic aciduria.
• Immune System: Tafazzin deficiency and resulting abnormal cardiolipin remodeling is associated with neutropenia, and anticardiolipin antibodies are central to the pathophysiology of antiphospholipid syndrome. Studies showed the link between anticardiolipin antibodies and stroke, deep vein thrombosis, recurrent pregnancy loss, livedo, and seizures.
• Nervous System: CL is associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its role in mitochondrial quality control is thought to be relevant to neuronal survival.
• Metabolic System: Pathological remodeling of CL has been implicated in the etiology of mitochondrial dysfunction commonly associated with diabetes, obesity, and heart failure. The biological functions of CL are thought to depend on its acyl chain composition, which is dominated by linoleic acids in metabolically active tissues.
• Apoptotic/Cell Death Pathways: Mitochondria play a key role in the apoptotic process; their damage activates a series of events which provoke the release of cytochrome c and other pro-apoptotic factors from the mitochondrial intermembrane space, and culminate in cell death.

7. Cardiolipin as a Biomarker

Due to the variety and tissue specificity of the four acyl chains and their sensitivity to oxidation, CL has been used as a biomarker in several diseases and disorders. In the early pathology of Type II diabetes, oxidized CL has been observed in circulating plasma.

Measurement of cardiolipin content and species composition in tissue biopsies is used experimentally to assess the degree of mitochondrial dysfunction and the stage of conditions such as heart failure, Barth syndrome, and diabetic cardiomyopathy. Neuronal-specific CL species have been detected in circulating blood in injury models, raising interest in CL as a circulating biomarker of mitochondrial injury. These applications remain in the research phase and are not yet standard clinical tools.

8. Cardiolipin-Targeting Therapeutic Strategies: The Elamipretide (SS-31) Model

Because exogenous cardiolipin does not readily cross cell membranes and reach the IMM in sufficient quantities, the primary pharmacological strategy for "supplementing" or supporting cardiolipin function involves compounds that target endogenous CL. The most studied is elamipretide (also known as SS-31, MTP-131, and Bendavia).

Elamipretide (SS-31) is a tetrapeptide being developed for use in a variety of mitochondrial disorders, including Friedreich's ataxia, mitochondrial myopathy, and Barth syndrome. It is believed to stabilize cardiolipin in the mitochondrial membrane, leading to improved mitochondrial function and decreased levels of toxic reactive oxygen species production. In animal and cellular models, elamipretide has reversed mitochondrial fragmentation and markers of disease in models of mitochondrial cardiomyopathies, Barth syndrome, and other disorders.

In clinical trials in multiple mitochondrial disorders, elamipretide has been well tolerated and shows preliminary evidence of benefit.

Preclinical studies suggest benefits in muscle aging, atherosclerosis, ischemia, osteoarthritis, diabetes, and glaucoma. But clinical trials in heart failure and primary mitochondrial myopathy have failed to meet primary endpoints.

The dietary approach to supporting cardiolipin involves ensuring adequate intake of linoleic acid, which is essential for the remodeling of nascent cardiolipin into its mature, biologically functional form. These findings support accumulating evidence for the potential cardiovascular benefits of dietary linoleic acid and highlight a unique biological role of this essential fatty acid not routinely considered in nutritional studies, that may have important implications for myocardial health and disease.

9. Dosage Forms and Reported Dosages

Because cardiolipin is not commonly sold as a stand-alone human dietary supplement, dosage data comes primarily from research on (a) cardiolipin-targeting compounds studied in clinical trials, and (b) dietary supplementation of its key precursor, linoleic acid.

9.1 Elamipretide (Cardiolipin-Targeting Peptide) in Clinical Trials

• SS-31 is well-tolerated as an intravenous infusion over a wide dose range (0.01 mg/kg/h to 0.25 mg/kg/h over 4 hours) in humans.
• A dose of 0.05 mg/kg/hr for 1 hour was used in the phase 2a clinical trial in patients with acute myocardial infarction with percutaneous coronary intervention.
• Doses of 4 mg and 40 mg once daily (subcutaneous) were tested in a phase 2 double-blind randomized controlled trial in heart failure.
• In the Barth syndrome crossover trial, study participants showed improvement in multiple clinical parameters, including muscle strength, exercise tolerance, and cardiac stroke volume, after 48 weeks of treatment.

9.2 Dietary Linoleic Acid Supplementation to Support Cardiolipin

• Male spontaneously hypertensive heart failure rats were administered diets supplemented with high-linoleate safflower oil or lard (10% w/w; 28% kilocalorie fat) or without supplemental fat (control) for 4 weeks. This was a preclinical (animal) study; corresponding human doses have not been established.
• The study demonstrates that supplementing the diet with high-linoleate safflower oil, limiting total fat consumption to less than 30% of kilocalorie intake, increases L4CL and total CL content in LV mitochondria.

No standardized human supplement dosage for isolated cardiolipin has been established in peer-reviewed literature. Cardiolipin is present naturally in organ meats and other animal tissues, but specific quantitative dietary intake recommendations for cardiolipin as an ingredient have not been published by any regulatory or advisory body.

10. Safety Considerations and Interactions

10.1 Safety of Elamipretide

SS-31 treatment leads to a few adverse events, though mostly mild. The most common adverse event with SS-31 is injection site reaction.

Over 700 patients have received elamipretide across major clinical trials. Safety data extends to 192 weeks (TAZPOWER trial).

Oral SS-31 appears to be safe and well-tolerated with no serious adverse effects in studied populations.

10.2 Anticardiolipin Antibodies and Autoimmune Interactions

An important clinical consideration is that antibodies directed against cardiolipin (anticardiolipin antibodies, aCL) are pathogenic in antiphospholipid syndrome. The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of pathogenic antiphospholipid antibodies. Lipid-binding aPL, which do not require a protein cofactor, include anticardiolipin antibodies, which are a diagnostic criterion of APS. Individuals with APS or suspected autoimmune conditions should be aware of this immune context when considering any cardiolipin-containing or cardiolipin-modifying supplement, though no interaction studies have been published in this specific clinical scenario.

10.3 Oxidative Susceptibility as a Safety-Relevant Property

The remodeling process is also believed to be responsible for generation of CL species that causes oxidative stress and mitochondrial dysfunction. The high degree of unsaturation of cardiolipin's acyl chains means that exogenous preparations, if poorly stabilized or oxidized, could in principle deliver peroxidized lipid species rather than intact CL. No human safety studies have specifically characterized the risk of oxidized cardiolipin ingestion at supplement doses.

10.4 Absence of Established Human Safety Database for Isolated Cardiolipin

Because cardiolipin as an isolated ingredient is not currently marketed at scale as a human dietary supplement, there are no published controlled human safety studies, no established tolerable upper intake levels, and no pharmacovigilance data for oral administration at supplemental doses. The safety of cardiolipin as naturally consumed in foods (e.g., beef heart, liver) is implied by its longstanding presence in the human diet, but this does not extend directly to concentrated or isolated preparations.

11. Summary of Evidence Strength

• Established science: Cardiolipin's essential structural and functional roles in the inner mitochondrial membrane, electron transport chain, and apoptosis regulation are very well-established by decades of biochemical and cell biology research.
• Genetic disease (Barth syndrome): The causal link between tafazzin mutations, cardiolipin remodeling defects, and clinical disease is firmly established. Small human clinical trial evidence for cardiolipin-targeted therapy (elamipretide) exists but is preliminary.
• Heart failure, diabetes, aging, neurodegeneration: Evidence is predominantly preclinical (animal models, cell culture). Human clinical trials of cardiolipin-targeting strategies have been conducted but have largely failed to meet primary endpoints in broader disease populations.
• Dietary linoleic acid as a cardiolipin precursor: Animal model evidence supports the concept that dietary linoleic acid can preserve cardiac cardiolipin and mitochondrial function; human clinical data for this specific mechanism are not established.
• Cardiolipin as isolated human supplement: No adequately powered, placebo-controlled human clinical trials of isolated oral cardiolipin supplementation have been published in the peer-reviewed literature.

References

• LIPID MAPS LipidWeb: Cardiolipin (Diphosphatidylglycerol) — composition, biochemistry and function
• Unraveling the mechanisms of cardiolipin function: The role of oxidative polymerization of unsaturated acyl chains — PMC
• Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease: Molecular and Pharmacological Aspects — PMC
• Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease — PubMed
• Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis — PubMed
• Cardiolipin and apoptosis — PubMed
• Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease — PubMed
• Role of cardiolipin in mitochondrial diseases and apoptosis — PubMed
• Role of Cardiolipin in Mitochondrial Signaling Pathways — Frontiers in Cell and Developmental Biology
• Barth syndrome: A life-threatening disorder caused by abnormal cardiolipin remodeling — PMC
• Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells — PMC
• Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome — PMC
• Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in the failing rat heart — PMC
• Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in the failing rat heart — PubMed
• Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases — PMC
• Cardiolipin, Perhydroxyl Radicals, and Lipid Peroxidation in Mitochondrial Dysfunctions and Aging — PMC
• Selective remodeling of cardiolipin fatty acids in the aged rat heart — PMC
• Alterations in Myocardial Cardiolipin Content and Composition Occur at the Very Earliest Stages of Diabetes — PMC
• Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies — PMC
• The Role of Cardiolipin in Mitochondrial Function and Neurodegenerative Diseases — PMC
• Cardiolipin and mitochondrial membrane integrity in neurodegeneration: insights from α-synuclein-driven Parkinson's disease — PMC
• The role of cardiolipin in mitochondrial dynamics and quality control in neuronal ischemia/reperfusion injury — PMC
• Targeting cardiolipin modification in a genetic disorder (ASBMB Today)
• SS-31 (Elamipretide): Cognitive Vitality For Researchers — Alzheimer's Drug Discovery Foundation
• FRDA Investigator Initiated Study with Elamipretide — ClinicalTrials.gov Protocol
• Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome — Taylor & Francis
• Antiphospholipid syndrome: A diagnostic challenge — PMC
• Antiphospholipid Antibodies — Johns Hopkins Lupus Center
• Turnover of nonessential fatty acids in cardiolipin from the rat heart — PMC